Biotech Values

[DewDiligence]

CMC is a sort of universal "gotcha" for drug/biotech companies.

MNTA's 40mg Copaxone is a case in point. SNY/REGN's Sarilumab is another (#msg-126139243, #msg-126123492). Genzyme (now SNY) had a CMC issue a few years ago that shut down one of the company's two main plants for an extended period and ended up costing hundreds of millions, if not billions, of dollars.